When Should Antithrombotic Therapy Be Restarted After GI Bleeding?: CGH | July 2026

Introduction:

After GI bleeding, clinicians face a difficult balance: restarting antithrombotic therapy too early may increase rebleeding, while delaying it may expose patients to cardiovascular or thromboembolic events. This meta-analysis examined the outcomes and timing of antithrombotic resumption after GI bleeding.

Why was this study needed?

The optimal timing for restarting antithrombotic therapy remains uncertain.

Prolonged interruption increases thrombotic risk.

Early resumption may increase recurrent GI bleeding.

Clinicians need a practical balance between hemostatic security and vascular protection.

Key Findings:

The meta-analysis included 21 studies evaluating antithrombotic resumption after GI bleeding.

Resuming antiplatelet therapy was associated with fewer major vascular events (HR 0.70).

Resumption was also associated with substantially lower mortality (HR 0.44).

However, recurrent GI bleeding increased (HR 1.42).

Timing analyses suggested that restarting antithrombotic therapy within approximately 7 days may reduce vascular events.

Earlier resumption comes at the cost of a higher rebleeding risk.

The optimal timing therefore depends on the bleeding lesion, adequacy of hemostasis, and underlying thrombotic indication.

Most available evidence is observational, so 7 days should not be interpreted as a universal restart rule.

Bottom Line:

Restarting antithrombotic therapy after GI bleeding appears to reduce vascular events and mortality despite increased rebleeding. Earlier resumption—often within about 7 days—may be appropriate after secure hemostasis, but timing must be individualized to bleeding and thrombotic risk.